Meeting Banner
Abstract #4483

Dynamic Hyperpolarized 13C CS-EPSI of Human Prostate Cancer – Initial Experience on 17 Patients Testing Acquisition & Quantitative Analysis Methods

Hsin-Yu Chen1, Peder E.Z. Larson1, Jeremy W. Gordon1, Robert A. Bok1, Marcus Ferrone2, Sue M. Noworolski1, Mark van Criekinge1, James B. Slater1, Lucas Carvajal1, Natalie Korn1, Rahul Aggarwal3, Sarah J. Nelson1, Pamela N. Munster3, John Kurhanewicz1, and Daniel B. Vigneron1

1Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, United States, 2Department of Clinical Pharmacy, University of California, San Francisco, San Francisco, CA, United States, 3School of Medicine, University of California, San Francisco, San Francisco, CA, United States

New hyperpolarized-13C MRI instrumentation and methods enabled phase II clinical studies on 17 prostate cancer patients using 3D dynamic CS-EPSI with 0.5cm3 spatial and 2s time resolution. New manufacturing processes for 13C-pyruvate provided more consistent polarization levels, pyruvate concentrations, radical filtrations for reliable and safe patient injections. Improved quantitative methods were designed and implemented for reproducible kinetic modeling, correction for receiver profile, and peak detection, accounting for B0 inhomogeneity and noise characteristics. These studies have shown the ability to detect high pyruvate-to-lactate conversion rates in biopsy confirmed prostate cancer.

This abstract and the presentation materials are available to members only; a login is required.

Join Here

Abstract E-Poster Video